期刊文献+

多发性肌炎/皮肌炎的肺部病变特点分析 被引量:3

Clinical analysis of lung complications in polymyositis and dermatomyositis
下载PDF
导出
摘要 目的:探讨多发性肌炎和皮肌炎(PM/DM)患者的肺部病变特点,以利于临床诊断、指导治疗。方法:回顾性分析71例PM/DM的肺部影像学、肺功能测定、超声心动图资料及相关因素,并对上述资料进行比较分析。结果:PM/DM的肺部病变发生率为54.9%,其中肺间质病变(ILD)最多见,其次为胸膜炎和肺动脉高压,肺功能异常以小气道损害为主。合并ILD组发热、关节炎和抗Jo-1抗体阳性的发生率高,而肌酸激酶(CK)、谷草转氨酶(AST)显著低于无ILD组。DM组易伴发肿瘤。结论:PM/DM患者肺部病变发生率高,以ILD多见,其发生与发热、关节炎、CK、AST、抗Jo-1抗体有相关性。小气道是PM/DM的肺部病变的主要部位。 Objective:To explore the clinical features of pulmonary involvement in patients with polymyositis and dermatomyositis(PM/DM).Methods:The data of 71 cases of PM/DM were retrospectively reviewed,accounting for demographic and clinical parameters,chest imaging,lung function test and ultrasonic cardiography.Results:Thirty-nine (54.9%)ont of 71 patients developed PM/DM-associated lung disease,including 34 cases (47.9%)of interstitial lung disease,8 cases (11.3%)of pleuritis and 5 cases (7.0%)of pulmonary artery hypertension.Small airway dysfunction was the most common finding in pulmonary function test.The patients with interstitial lung disease had higher prevalence of fever,arthritis and anti-Jo-1 antibody positivity,however,the creatine kinase(CK) and aspartate aminotransferase(AST) were significantly lower in PM/DM patients without interstitial lung disease.DM patients were prone to complicate with tumor.Conclusion:Lung disease was observed in 54.9% patients with PM/DM.Interstitial lung disease was the main pulmonary involvement,and asso- ciated with fever,arthritis,CK,AST,and anti-Jo-1 antibody.The small airway was the most common target site in lung disease.
出处 《中日友好医院学报》 2008年第1期17-19,27,共4页 Journal of China-Japan Friendship Hospital
关键词 皮肌炎 多发性肌炎 肺部病变 dermatomyositis polymyositis lung disease
  • 相关文献

参考文献9

  • 1Kameda H, Takeuchi T.Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dennatomyositis [J].Endocr Metab Immune Disord Drug Targets, 2006,6(4) :409-415.
  • 2Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X,et al.PM/DM-associated lung disease:analysis of a series of 81 patients [J].Lupus,2005,14(7) :534-542.
  • 3Kang EH,Lee EB,Shin KC,et al. Interstitial lung disease in patients with polymyositis,dermatomyositis and amyopathic dermatomyositis [J].Rheumatology (Oxford), 2005,44 (10) : 1282-1286.
  • 4Fathi M,Dastmalchi M,Rasmussen E, et al. Interstitial lung disease,a common manifestation of newly diagnosed polymyositis and dermatomyositis [J].Ann Rheum Dis, 2004,63(3) :297-301.
  • 5Marie I,Hachulia E,Cherin P,et al. Interstitial lung disease in polymyositis and dermatomyositis [J].Arthfitis Rheum, 2002,47 (6) : 614-622.
  • 6Ito M,Kaise S,Suzuki S,et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease [J].Clin Rhrumatol, 1999,18(6) :462-467.
  • 7Takada T,Suzuki E,Nakano M,et al.Clinical features of polymyositis /dermatomyositis with steroid-resistant interstitial lung disease [J].Intern Med, 1998,37(8) :669-673.
  • 8卢昕,谢瑶,王国春.血清KL-6检测在特发性炎性肌病伴肺间质病变诊断中的价值[J].中华风湿病学杂志,2006,10(7):416-419. 被引量:15
  • 9Dalakas MC, Hohfeld R.Polymyositis and dermatomyositis [J]. Lancet, 2003,362 (9388) : 971-982.

二级参考文献10

  • 1Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and diffusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma.Jpn J Clin Oncol, 1985, 18: 203-206.
  • 2Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis, 1993, 148: 637-642.
  • 3Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest, 1989, 96: 68-73.
  • 4Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum, 2002, 47:614-622.
  • 5Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol, 2000, 27:1164-1170.
  • 6Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med, 2002, 165: 378-381.
  • 7Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford),2000, 39: 632-636.
  • 8Inoue Y, Nishimura K, Shiode M, et al. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis,1995, 76: 230-233.
  • 9Sato H, Callister ME, Mumby S, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome.Eur Respir J, 2004, 23: 142-145.
  • 10Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis, 2004, 63: 297-301.

共引文献14

同被引文献42

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部